The Brussels Desk · IndependentBrussels desk
What It MeansMonday, 16 November 2026 · 2 min read

Green Lights and Red Tape: EU Medicines Watchdog Backs 18 Treatments in Busy November Session

The EMA’s scientific committee issues seven new approvals and eleven extensions, warning drugmakers that clearing review is only the first hurdle.

By Nina Marchetti · Filed Monday, 16 November 2026 · Last updated 10:00 CET

Share

What happened

The European Medicines Agency’s drug review arm, the Committee for Medicinal Products for Human Use (CHMP), concluded its November meeting with positive verdicts for 18 treatments. The scientific panel recommended green lights for seven brand-new drug authorisations and backed expanding the use of eleven existing medicines into new therapeutic indications. Alongside the approvals, the watchdog highlighted a mounting regulatory hurdle: substantial post-authorisation evidence requirements that pharmaceutical sponsors frequently underestimate before heading to market.

Why it matters

For European patients, a positive CHMP verdict is the critical scientific milestone determining whether cutting-edge treatments reach domestic pharmacies and hospitals. However, the committee's emphasis on post-approval evidence reflects a growing trend in medicines regulation. Regulators increasingly grant market access based on preliminary or targeted clinical trial data on the condition that manufacturers continue gathering real-world safety and efficacy proof once the drug is in wider circulation. For drugmakers, winning the committee's nod is no longer the finish line; it is an entry ticket to continuous, costly paperwork.

The Brussels angle

In the EU's healthcare machinery, the CHMP is the ultimate gatekeeper, translating reams of clinical trials into scientific recommendations. While the committee issues the verdict, it cannot formally sign the paperwork. That duty falls to the European Commission, which nearly always converts CHMP scientific opinions into legally binding, pan-European marketing authorisations with quiet institutional deference. To an outside observer, it looks like double handling; inside the Brussels health policy apparatus, it is the deliberate separation between the scientists who assess the medicine and the executive that accepts legal responsibility for putting it on the single market.

What happens next

The positive opinions now head to the European Commission for formal sign-off, typically granted within a standard two-month comitology window. Once Brussels rubber-stamps the authorisations, national health ministries take over the bruising task of negotiating domestic prices and reimbursement. Meanwhile, the sponsors of the approved drugs face the administrative task of launching their post-marketing monitoring programmes to keep their regulatory clearances intact.

emachmppharmaceuticalshealthmedicines

Written from these sources

Facts are extracted from primary institutional material and written independently by The Gazette desk.

Explainer Desk Editor · EU 101 and What It Means

Nina Marchetti

Nina Marchetti edits the Explainer Desk, turning complicated EU announcements into plain English for readers who have never sat through a Commission briefing.

More from Nina Marchetti →

The Brief

Brussels, decoded, every morning. What happened, what it means, one good dry joke.